Atossa Therapeutics issued U.S. patent covering endoxifen formulations

Atossa Therapeutics (ATOS) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,479,790 B2, titled, “Methods for Making and Using Endoxifen.” The newly issued patent includes 100 claims directed to enteric oral formulations of highly pure (Z)-endoxifen free base, as well as methods of using those compositions to treat a range of hormone-dependent breast disorders and other estrogen-related conditions. The patent also covers specific solid oral dosage forms and stable formulations providing therapeutically meaningful and sustained systemic exposure to (Z)-endoxifen.